Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $29.90 and last traded at $28.41, with a volume of 857700 shares trading hands. The stock had previously closed at $27.69.

A number of brokerages have recently issued reports on ADMS. Mizuho reaffirmed a “buy” rating and set a $26.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, September 5th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 20th. Noble Financial reaffirmed a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Finally, Evercore ISI began coverage on Adamas Pharmaceuticals in a research note on Monday, October 30th. They set an “outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. Adamas Pharmaceuticals currently has an average rating of “Buy” and an average price target of $42.00.

The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.03). The firm’s quarterly revenue was down 99.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.66) EPS. analysts predict that Adamas Pharmaceuticals, Inc. will post -3.87 EPS for the current year.

Several institutional investors have recently bought and sold shares of ADMS. Macquarie Group Ltd. purchased a new stake in shares of Adamas Pharmaceuticals during the third quarter worth about $15,899,000. Point72 Asset Management L.P. boosted its holdings in shares of Adamas Pharmaceuticals by 639.3% during the third quarter. Point72 Asset Management L.P. now owns 850,165 shares of the specialty pharmaceutical company’s stock worth $17,998,000 after purchasing an additional 735,165 shares during the period. Axiom International Investors LLC DE boosted its holdings in shares of Adamas Pharmaceuticals by 134.1% during the third quarter. Axiom International Investors LLC DE now owns 236,209 shares of the specialty pharmaceutical company’s stock worth $5,001,000 after purchasing an additional 135,297 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Adamas Pharmaceuticals by 13,028.4% during the third quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 135,235 shares during the period. Finally, EAM Investors LLC purchased a new stake in shares of Adamas Pharmaceuticals during the third quarter worth about $1,795,000. Institutional investors own 76.24% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Adamas Pharmaceuticals, Inc. (ADMS) Hits New 52-Week High at $29.90” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/20/adamas-pharmaceuticals-inc-adms-hits-new-52-week-high-at-29-90.html.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.